Navigation Links
Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
Date:4/21/2008

Second Phase Opens With Higher Dose Regimens

SAN MARINO, Calif., April 21 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer. The clinical trial design includes 5 escalating doses of intravenous Rexin-G ranging from 1 x 10e11 cfu twice a week to 4 x 10e11 cfu three times a week for 4 weeks. Treatment cycles are repeated if the patient exhibits Grade 1 or less toxicity. Interim analysis showed no dose limiting toxicities in 9 evaluable patients who received Dose Levels 1-3. Furthermore, the analysis showed decrease in tumor size or disease stabilization (by RECIST), decreased metabolic activity in tumors (by PET-CT scan), reduction in tumor marker levels, and clinical benefit in patients receiving Dose Level 3. The second phase of the Rexin-G study has now opened wherein six patients will receive Dose levels 4 and 5, respectively, as the Phase I/II adaptive study design continues to evaluate the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the clinical benefits required to support a Phase II/III pivotal trial.

*(LOGO: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

According to Dr. Sant P. Chawla, Principal Investigator of the Phase I/II study, "I am happy with the positive results of Rexin-G seen in pancreatic cancer, and look forward to obtaining even better results with progressively higher doses of Rexin-G." Dr. Chawla is currently conducting three Los Angeles-based Phase I/II clinical trials using Rexin-G in sarcoma, pancreatic cancer, and breast cancer, and a Phase II study of Rexin-G for osteosarcoma. For further information concerning these clinical trials, please contact Dr. Erlinda M. Gordon at

SOURCE Epeius Biotechnologies Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
2. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
3. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
6. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
7. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
8. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
9. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
10. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
11. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , BRIDGEWATER, N.J., Nov. 25 T...#174; (etravirine) tablets, a non-nucleoside rever...he only NNRTI specifically indicated for use in tr...rologic failure with HIV-1 strains resistant to an... traditional approval is based on 48-week data fro...
(Date:11/25/2009)... , RANCHO CORDOVA, Calif., Nov. 25 /PRNewswire...of American Pacific Corporation (Nasdaq: APFC ) a...Responsibility and Sustainability Award at the Ann...he California Manufacturers and Technology Associa...ion (IEA) and the Chemical Industry Council of Cal...
(Date:11/25/2009)... , NEW YORK, Nov. 25 Rep... report is available in its catalogue: ,, Unit...asts to 2015 ,, http://www.reportlinker.com/p...is-and-Forecasts-to-2015.html ,, United States...015 ,, Summary ,, This report is an essent...
Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13Reportlinker Adds Wound Care Markets 4th Edition Vol II 3A Burns Report 57992 1Reportlinker Adds Wound Care Markets 4th Edition Vol II 3A Burns Report 57992 2Reportlinker Adds Wound Care Markets 4th Edition Vol II 3A Burns Report 57992 3Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 1Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 2Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 3Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 4Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 5Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 6Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 7Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 8Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 9Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 10Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 11Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 12Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 13Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 14Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 15Democratic Governors Urge Congress to Act on Health Insurance Reform 57988 1Democratic Governors Urge Congress to Act on Health Insurance Reform 57988 2
...re-FirstCall/ - Oncolytics,Biotech Inc. ("Oncolyti...e et al. of , New York, entitled "In Vivo Synergy ...Mutated Human HCT116,Xenografts" is scheduled to b...Cancer Research (AACR) Annual Meeting in Los,Angel... The researchers found that treatment of human col...
...17, 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB)...I data on the Company,s prostate cancer drug candi... the American Association for,Cancer Research (AAC...data was presented in two oral presentations as pa... Late-Breaking Clinical,Trials. These presentation...
Other Medicine Technology:Oncolytics Biotech Inc. Research Collaborators Demonstrate,Reovirus/Gemcitabine Combination Has Synergistic Effect Against,Human Colon Cancer Cell Lines 2Oncolytics Biotech Inc. Research Collaborators Demonstrate,Reovirus/Gemcitabine Combination Has Synergistic Effect Against,Human Colon Cancer Cell Lines 3Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session 2Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session 3Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session 4Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR,Annual Meeting Late-Breaking Clinical Trials Session 5
(Date:11/27/2009)...AMIR, Israel, Nov. 27 Sh...mir" ), a leading provider of innovative products ...unced today that its board of directors had declar...of US$ 10 million (approximately NIS 37.62 million...e of exchange), or approximately US$ 0.609 (approx...
(Date:11/27/2009)...g unprecedented medical, economic burdens, study p...ews) -- The number of people with diabetes in the ...25 years, a new study predicts. , That would br... with the disease, up from 23.7 million today. , ...ith diabetes will triple, the study also warns, ri...
(Date:11/27/2009)... Multi-purpose bilingual coloring books design...the business community to educate - inform parents...Safety issues to Dinosuars to ABC,S and a host of ...is, MO (PRWEB) November 27, 2009 -- Today’s ...to keep them busy any hour of the day, but one of ...
(Date:11/26/2009)... Nov. 27 With cold and flu season ...ood practices to control the spread of infections ...not only to keep ourselves healthy, but to avoid t...nerty, RN, MS, CIC (certified in infection-control...pational health at Hospital for Special Surgery (H...
(Date:11/26/2009)...ring drug tetrathiomolybdate (TM) has been shown i...on disease, a disease caused by an overload of cop...known. Very little, however, is known about how th...dy led by Northwestern University researchers now ...onal structure of TM bound to copper-loaded metall...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3
... at St. Louis Children's Hospital and Washington U...uested authorities not to allow children under the.... This call was issued after a 10-year review of t...see what's coming up ahead of them very well,' say...
...lege Dublin has joined hands with Florida-based Ro...essure drug Nilvadipine and its possible use in Al...arch Network (DARN). Doctors of Geriatrics and Old... the Adelaide and Meath Hospital and St Patrick’s ...
...ines and aphrodisiacs, Nepal, a treasury of potent...e. // "Hill Hot" is the brainchild of Jhalak...ern Nepal, whose life is as piquant as his novel e...pal's markets along with foreign beers, whiskeys a...
...y St. Jude finds that by tailoring the intensity o...rt the length of intensive chemotherapy improves o... A team of investigators led by St. Jude Childre...vival of children with this disease. The tr...
... and maintenance of strong bones, strong and healt...the mineral, calcium.// It is vital to take p...iod, to protect bones later in life and to prevent...roducts, leafy green vegetables, dried beans and f...
... reveals the details of how drugs are released wit...University of Purdue has shown for the first time ...ncer cell, which could lead in the improving of th...s into every cell of the body for the treatment of...
Other Medicine News:Health News:Call To Ban Use Of ATVs By Children 2Health News:Nepal Uncorks 'Herbal Wine' 2Health News:Survival rates improve with better treatment options for medulloblastoma 2Health News:Survival rates improve with better treatment options for medulloblastoma 3Health News:Study Findings Could Help In Developing A Better Drug Delivery System 2Health News:Study Findings Could Help In Developing A Better Drug Delivery System 3Health News:Study Findings Could Help In Developing A Better Drug Delivery System 4
Replacement Bulb: EFP
Replacement Bulb: EFM
Replacement Bulb: DNE Osram Sylvania
Replacement Bulb: DDL
Medicine Products: